Korean J Gastroenterol.  2013 Jun;61(6):354-355. 10.4166/kjg.2013.61.6.354.

The Efficacy and Safety of a Tofacitinib in the Treatment of Active Ulcerative Colitis

• Seo GS

• KMID: 1718070
• DOI: http://doi.org/10.4166/kjg.2013.61.6.354

Abstract

No abstract available.

MeSH Terms

Colitis, Ulcerative/*drug therapy
Female
Humans
Janus Kinases/*antagonists & inhibitors
Male
Protein Kinase Inhibitors/*administration & dosage
Pyrimidines/*administration & dosage
Pyrroles/*administration & dosage
Janus Kinases
Protein Kinase Inhibitors
Pyrimidines
Pyrroles

Reference

References

1. Sandborn WJ, Ghosh S, Panes J, et al. Study A3921063 Investigators. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367:616–624.

2. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302:875–878.

3. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation. 2005; 80:1283–1292.

4. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012; 12:2446–2456.

5. van Vollenhoven RF, Fleischmann R, Cohen S, et al. ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367:508–519.

6. van der Heijde D, Tanaka Y, Fleischmann R, et al. ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013; 65:559–570.

7. Burmester GR, Blanco R, Charles-Schoeman C, et al. ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013; 381:451–460.

8. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009; 129:2299–2302.

9. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012; 167:668–677.